A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06744920
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Completed
- Conditions
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 175
- Registration Number
- NCT06737419
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Phase 4
Recruiting
- Conditions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06733922
- Locations
- 🇨🇦
Novartis Investigative Site, Lévis, Quebec, Canada
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT06726148
A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
Terminated
- Conditions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT06715254
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 316
- Registration Number
- NCT06711887
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT06704269
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
Completed
- Conditions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 438
- Registration Number
- NCT06699914
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
Completed
- Conditions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2043
- Registration Number
- NCT06692803
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT06684964
© Copyright 2024. All Rights Reserved by MedPath